Company Overview
Snapshot
Founded in November 2020 by Sahar Meiron, Hilik Marom, and Dr. Tami Ehrmann-Barr, OrthoTreat operates with 11–50 employees. The company has completed 2 funding rounds to date. In July 2023, OrthoTreat secured Seed funding.
Business overview
OrthoTreat is dedicated to advancing bone regeneration solutions, focusing on empowering healing for individuals with bone-related conditions. The company's core technology involves a unique approach to modulating complex bone regeneration processes, specifically by balancing immune response, inflammation, and growth factor secretion. Its flagship product, ModulX, is a dual-drug combination delivered via a controlled-release, localized injection designed to accelerate healing and improve bone quality. OrthoTreat operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving global markets.
Strategic signal
In January 2025, OrthoTreat was recognized as a winner in the Healthcare & Pharmaceuticals Awards. This accolade highlights the company's innovative contributions to the healthcare industry and signals external validation of its approach to bone regeneration, reinforcing its potential for impact in the market.
Log in to access full profile ›Company Intelligence Q&A
- What is OrthoTreat's primary product?
- OrthoTreat's primary product is ModulX, a dual-drug combination administered as a controlled-release, localized injection designed to accelerate healing and improve bone quality.
- When was OrthoTreat founded?
- OrthoTreat was founded in November 2020.
- Who are the founders of OrthoTreat?
- OrthoTreat was founded by Sahar Meiron, Hilik Marom, and Dr. Tami Ehrmann-Barr.
- What recent recognition did OrthoTreat receive?
- In January 2025, OrthoTreat was named a winner in the Healthcare & Pharmaceuticals Awards.
- What was OrthoTreat's most recent funding event?
- OrthoTreat secured Seed funding in July 2023.